<DOC>
	<DOCNO>NCT01063907</DOCNO>
	<brief_summary>The purpose study assess safety benefit investigational study drug , KW-2478 , give bortezomib ( Velcade® ) , drug approve treatment Multiple Myeloma ( MM ) . The primary objective : - To establish safety , tolerability , recommend Phase II dose ( RP2D ) KW-2478 combination bortezomib ( Phase I ) ; - To assess overall response rate ( ORR ) subject advanced MM treat ( Phase II ) . The secondary objective : - To characterize Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) KW-2478 bortezomib ( Phase I ) ; - To evaluate preliminary evidence efficacy ( Phase I ) ; - To determine progression free survival ( PFS ) duration response KW-2478 bortezomib ( Phase II ) .</brief_summary>
	<brief_title>A Study KW-2478 Combination With Bortezomib Subjects With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description>This multicenter , open label , dose escalation , Phase I / II study subject relapse and/or refractory MM . Up 24 subject enrol Phase I determine RP2D . Up 77 additional evaluable subject enrol Phase II maximum 101 subject treat study . Study center USA UK participate Phase I II . Centers Philippines participate Phase II . The planned enrollment period 22 month plan study duration 28 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Accepts Healthy Volunteers : No 1 . Subjects confirm diagnosis Multiple Myeloma one three prior regimen MM respond ( fail ) relapse . 2 . Signed either IRB IEC approve informed consent 3 . ECOG performance status ≤ 2 4 . Life expectancy least 3 month 5 . M protein either serum urine , free light chain measurable M protein serum urine , clonal bone marrow plasma cell &gt; 10 % , evidence end organ damage 6 . Adequate hematologic status , liver renal function 7 . Subjects reproductive potential must agree follow accepted pregnancy prevention method study . 1 . No anticancer treatment ≥ 4 week bortezomib treatment ≥ 60 day prior receive study drug 2 . Any severe , acute chronic illness 3 . No prior concurrent malignancy 4 . No immunosuppressant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Immunoproliferative Disorder</keyword>
	<keyword>Neoplasma Histologic Type</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Blood Protein Disorders</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Hematologic Disorders</keyword>
	<keyword>Leukemia , Chronic , B-cell</keyword>
	<keyword>Leukemia , B-cell</keyword>
	<keyword>Leukemia , Chronic</keyword>
	<keyword>Neoplasms , Plasma Cell</keyword>
	<keyword>Monoclonal Gammopathy unknown significance ( MGUS )</keyword>
</DOC>